Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
Executive Summary
During third-quarter earnings report, Brandicourt said he remains confident about Sanofi's prospects in oncology despite losing the takeover fight for Medivation, although he didn't rule out another mid-sized bolt-on attempt if the opportunity arose.
You may also be interested in...
Sarilumab Set To Clear EU Hurdle In RA But Actemra Specter Remains
While Sanofi/Regeneron's sarilumab is set to be the first of the newer IL-6 products to be cleared for rheumatoid arthritis treatment in Europe and the US, its commercial success is under doubt with physicians trying anti-TNF treatments first, followed by Roche's established IL-6 drug Actemra (tocilizumab).
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.
Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.